EUVIMEDEUVIMED entdecken
Crossref

Low CD4 counts predict excessive weight gains during first-line treatment for HIV

Andrew Hill iD, Tamara Tovar Sanchez, Eric Delaporte, Simiso Sokhela iD, Bryony Simmons, Charles Kouanfack iD, Kaitlyn Mccann, Jacob Levi iD, Cassandra Fairhead, Francois Venter iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Andrew Hill und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Liverpool, Department of Pharmacology and Therapeutics, 70 Pembroke Place, Liverpool L69 3GF, Liverpool, UK. Hauptthemen laut MEDLINE: HIV Infections, Weight Gain, Anti-HIV Agents, Benzoxazines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: TRIO, NAMSAL, French National Agency for AIDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Weight gain is common after antiretroviral initiation, especially among females, those of black race and lower baseline CD4, although this may potentially be due to lower baseline weight. Use of tenofovir disoproxil fumarate or efavirenz can suppress weight gain.

Methods

Data were pooled from the ADVANCE (n = 1053), NAMSAL (n = 613) and WHRI001 (n = 536) trials investigating first-line regimen. Week 96 weight and body mass index (BMI) was stratified by baseline CD4. Multivariable models of weight change and incident obesity (BMI ≥30 kg/m2) were adjusted for baseline CD4, age, sex, tenofovir disoproxil fumarate, efavirenz, baseline BMI and trial.

Results

Participants across all treatment arms experienced weight gain from baseline to week 96, with baseline CD4 count, baseline HIV RNA, tenofovir alafenamide and dolutegravir use, and female sex significant predictors. Mean unadjusted weight change was highest with CD4 < 100 (+8.6 kg; SD = 8.2) and lowest with CD4 ≥ 350 (+3.0 kg; SD = 6.5). This weight gain in CD4 < 100 was highest for participants on tenofovir alafenamide-inclusive treatment, such that absolute weight at week 96 was highest in the CD4 < 100 group. Although not statistically significant, obesity rate (BMI ≥ 30 kg/m2) in those taking TAF/FTC + DTG with CD4 < 100 overtook that seen in CD4 ≥ 350, despite lower baseline obesity prevalence. The unadjusted findings were corroborated in multivariable longitudinal models.

Conclusions

Participants with low CD4 may demonstrate significant ‘overshoot’ weight gain, in addition to ‘return to health’, with a trend towards increased risk of obesity when initiated on TAF/FTC + DTG. Use of tenofovir disoproxil fumarate and efavirenz were associated with smaller weight gains. Effective weight management strategies are needed, especially for individuals with low baseline CD4.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsWeight GainAnti-HIV AgentsBenzoxazinesAlkynesTenofovirCyclopropanesHumansFemaleMaleCD4 Lymphocyte CountAdultMiddle AgedOxazinesBody Mass IndexObesity

Substanzen

Anti-HIV AgentsBenzoxazinesefavirenzAlkynesTenofovirCyclopropanesOxazines

Autor:innen und Institutionen

  • University of Liverpool, Department of Pharmacology and Therapeutics, 70 Pembroke Place, Liverpool L69 3GF, Liverpool, UK.
  • Department of Infectious Diseases, University of Montpellier, TransVIHMI, Institute de Recherche pour le Développement, Inserm Montpellier, France.
  • Department of HIV, Wits Ezintsha, University of the Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa.
  • Department of Health Economics, London School of Economics and Political Science, LSE Health, London, UK.
  • Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.
  • Department of Public Health, Imperial College London, Faculty of Medicine, London, UK.

ORCID-Profile: Andrew Hill, Simiso Sokhela, Charles Kouanfack, Jacob Levi, Francois Venter

Förderung

  • TRIO
  • NAMSAL
  • French National Agency for AIDS
  • Emerging Infectious Diseases Research
  • Unitaid

Zitieren

APA

Hill, A., Tovar Sanchez, T., Delaporte, E., Sokhela, S., Simmons, B., Kouanfack, C., Mccann, K., Levi, J., Fairhead, C., & Venter, F. (2024). Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae238

Vancouver

Hill A, Tovar Sanchez T, Delaporte E, Sokhela S, Simmons B, Kouanfack C, et al. Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae238

BibTeX
@article{Hill2024,
  author = {Hill, Andrew and Tovar Sanchez, Tamara and Delaporte, Eric and Sokhela, Simiso and Simmons, Bryony and Kouanfack, Charles and Mccann, Kaitlyn and Levi, Jacob and Fairhead, Cassandra and Venter, Francois},
  title = {Low CD4 counts predict excessive weight gains during first-line treatment for HIV},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae238}
}
Kostenlos starten →